Richard Thompson provides a concise overview of late-onset genetic cholestasis, including the pathophysiology and genetics behind the various phenotypes that can present, in this short, animated video.
General Information
Title: About late-onset genetic cholestasis
Release date: January 30th 2025
Estimated time to complete activity: 5 minutes
This program is made possible thanks to an independent educational grant from Ipsen
Target Audience
This activity is primarily aimed at a global audience of adult hepatologists and gastroenterologists, but is relevant to all members of the multidisciplinary team that manages late-onset genetic cholestatic patients.
Educational Objectives
After completing this activity, the participant should be better able to:
- Recognize the different phenotypes and clinical presentations of late-onset genetic cholestasis
Faculty
- Richard Thompson
King’s College London, United Kingdom
Disclosures
- Richard Thompson
Honoraria or consultation fees: CymaBay, Enanta, Genfit, GSK, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, 89bio, Zydus, Abbvie, Intercept, Gilead
Honoraria or consultation fees: Mirum, Ipsen, Rectify, Generation Bio, Integra, Spruce, Alnylam, Glycomine
Stocks, shares or equity: Generation Bio, Rectify, Integra
